Related Experiment Videos

[Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular

Shogen Boku1, Kaoru Araki-Sasaki, Keiko Sakaguchi

  • 1Dept. of Clinical Oncology, Kansai Medical University Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 4, 2026
PubMed
Abstract

Insights

Tisotumab vedotin (TV) can cause ocular adverse events (OAEs) in cervical cancer patients. An onco-ophthalmology system effectively managed a case of pseudomembranous conjunctivitis, enabling safe TV therapy continuation.

Area of Science:

  • Oncology
  • Ophthalmology
  • Pharmacology

Background:

  • Tisotumab vedotin (TV), an antibody-drug conjugate targeting tissue factor (TF), is approved for recurrent/metastatic cervical cancer.
  • TF expression on the ocular surface leads to frequent ocular adverse events (OAEs) with TV therapy.
  • An onco-ophthalmology collaboration system was established to manage TV-associated OAEs.

Purpose of the Study:

  • To report on the established onco-ophthalmology collaboration system for managing ocular risks associated with Tisotumab vedotin therapy.
  • To demonstrate the efficacy of a multidisciplinary approach in managing ocular complications during TV treatment.

Main Methods:

  • Implementation of a multidisciplinary protocol involving oncologists, ophthalmologists, pharmacists, and nurses.
  • Key strategies included pre-treatment ophthalmic assessment, prophylactic eye drops, cooling during infusion, and rapid referral.
  • Systematic monitoring and management of patients receiving TV therapy.

Main Results:

  • Five patients received TV therapy between June and October 2025.
  • One patient (20%) developed Grade 2 pseudomembranous conjunctivitis.
  • Early diagnosis and steroid treatment led to symptom resolution within 7 days.

Conclusions:

  • Ocular complications can occur despite preventative measures during TV therapy.
  • The onco-ophthalmology liaison system facilitates early diagnosis and effective management of OAEs.
  • This collaborative system ensures the safe continuation of Tisotumab vedotin therapy.

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...